These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Troglitazone: a review of its use in the management of type 2 diabetes mellitus. Plosker GL; Faulds D Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691 [TBL] [Abstract][Full Text] [Related]
7. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial. Katoh S; Hata S; Matsushima M; Ikemoto S; Inoue Y; Yokoyama J; Tajima N Metabolism; 2001 Apr; 50(4):414-7. PubMed ID: 11288035 [TBL] [Abstract][Full Text] [Related]
8. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. Johnson MD; Campbell LK; Campbell RK Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065 [TBL] [Abstract][Full Text] [Related]
9. Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. Marchesini G; Moscatiello S; Agostini F; Villanova N; Festi D Expert Opin Emerg Drugs; 2011 Mar; 16(1):121-36. PubMed ID: 21352073 [TBL] [Abstract][Full Text] [Related]
11. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Younossi ZM Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557 [TBL] [Abstract][Full Text] [Related]
12. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Kruszynska YT; Yu JG; Olefsky JM; Sobel BE Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202 [TBL] [Abstract][Full Text] [Related]
13. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Caldwell SH; Hespenheide EE; Redick JA; Iezzoni JC; Battle EH; Sheppard BL Am J Gastroenterol; 2001 Feb; 96(2):519-25. PubMed ID: 11232700 [TBL] [Abstract][Full Text] [Related]
15. Current treatment of non-alcoholic fatty liver disease. Ahmed MH; Byrne CD Diabetes Obes Metab; 2009 Mar; 11(3):188-95. PubMed ID: 18564173 [TBL] [Abstract][Full Text] [Related]
16. Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome. Yamakita T; Ishii T; Mori T; Yoshioka K; Sato T; Tanaka S; Kurimasa H; Fujita K; Fujii S Diabetes Res Clin Pract; 1998 Dec; 42(3):205-8. PubMed ID: 9925352 [TBL] [Abstract][Full Text] [Related]
17. Hepatotoxicity with thiazolidinediones: is it a class effect? Scheen AJ Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645 [TBL] [Abstract][Full Text] [Related]
18. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Walli R; Michl GM; Mühlbayer D; Brinkmann L; Goebel FD Res Exp Med (Berl); 2000 Apr; 199(5):253-62. PubMed ID: 10815754 [TBL] [Abstract][Full Text] [Related]
19. Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes. Jia DM; Tabaru A; Nakamura H; Fukumitsu KI; Akiyama T; Otsuki M Metabolism; 2000 Sep; 49(9):1167-75. PubMed ID: 11016899 [TBL] [Abstract][Full Text] [Related]